Ascensia Diabetes Care received clearance from the Food and Drug Administration to market its Countour Next One blood glucose monitoring system.
The system includes a blood glucose smart meter, which can connect to an app on a patient's mobile device to store and analyze blood glucose measurements, according to the report.
"We believe the future of healthcare lies in connecting points of care," Robert Schumm, head of Ascensia Diabetes Care U.S., said in a company news release. "The first step in that journey for diabetes is to provide a connected system, which can add value for people living with diabetes."
Parsippany, N.J.-based Ascensia Diabetes Care expects the Countour Next One Blood Glucose Monitoring System to hit the market in early 2017.
More articles on supply chain:
Texas Blood Center in desperate need of O-negative blood
5 trends on the growing role of digitization in supply chain
Novo Nordisk, Sanofi to battle for sales with new combination diabetes drugs: 4 takeaways